Reading time is 3 mins
.
.
KIDNEY CANCER! WHAT ARE THE SYMPTOMS?
Kidney cancer is a tumor that has increased in incidence all over the world and in our country and accounts for about 3 percent of adult cancer cases. It is observed 2 times more often in men than in women and usually occurs between ages of 40 and 70. Turkey Medicals member and Urologist Assoc. Dr. told you about what is curious about kidney cancer and its treatment for you.
There are about 400 thousand kidney cancer patients all over the world, and this number is expected to exceed 650 thousand in 2040. It is estimated that the number of kidney cancer cases in our country, which is about 5 thousand, will be 7800 in 2040.
.
WHAT ARE THE RISK FACTORS?
Some risk factors associated with the development of kidney cancer have been identified. These are smoking, obesity, high blood pressure, exposure to toxic chemical agents, and genetic causes that double the risk of developing the disease. Carcinogenic toxic substances contained in cigarette smoke are filtered through the kidneys, which act as a filter in the body after they enter the blood from the lungs. These toxic substances damage kidney cells and increase the risk of developing kidney cancer.
People with chronic kidney failure, patients on dialysis, and people who have had a kidney transplant have an increased risk of developing a kidney tumor. In addition, having a relative with kidney cancer in the family increases the risk of developing kidney cancer. It is known that the risk of developing kidney cancer is high in diseases with gene mutations, such as von Hippel-Lindau and tuberous sclerosis.
.
WHAT ARE THE SYMPTOMS?
In the vast majority of kidney cancer patients, the disease progresses insidiously without symptoms until later periods. But when it reaches the final stages and bounces to other organs, it causes complaints such as cough, bone pain, jaundice, weight loss. Most of the patients diagnosed at an early stage are detected by chance during radiological imaging methods performed for another reason. The classic symptoms of kidney cancer, such as blood coming from the urine, side pain, and mass coming to the hand, are only monitored in a small proportion of 10-15 percent of patients. Due to the fact that survival rates of more than 90 percent are achieved with early diagnosis, it is very important that people with a family history and risk factors do not disrupt routine urological checkups, especially.
.
HOW IS THE DIAGNOSIS MADE?
The patient’s history (anamnesis) and physical examination are the first steps towards reaching a diagnosis. During the examination, it is investigated whether there is stiffness or a mass coming to the hand, especially in the side areas of the abdomen where the kidneys are located. The patient’s complaints, history, and the doctor’s initial evaluation findings are very important to determine the research that will be done later. By looking at blood biochemistry and urine analysis as laboratory tests, information is obtained about whether there is bleeding in the urine and the function of the kidneys. Kidney cancer is usually diagnosed by imaging methods. For this purpose, radiological examinations such as Ultrasound (US), Tomography (CT), MRI examination and PET are used.
.
HOW IS THE TREATMENT PERFORMED?
The main method of treating kidney tumors is surgery. Depending on the size and location of the tumor, operations are performed to completely remove the tumor kidney (radical nephrectomy) or to remove only the tumor part (partial nephrectomy). Currently, these operations can also be performed by laparoscopic or robotic surgery in appropriate cases. For suitable patients with a small tumor, ablative treatments (microwave thermal ablation, radiofrequency ablation, cryotherapy) can be performed, in which only the part with the tumor is burned, protecting the kidney that we call. In this way, the tumor part can be destroyed without damaging the kidney. Again, in patients with a small tumor, when the risk of surgical intervention outweighs the oncological benefits that treatment will bring, close monitoring with active monitoring can be performed.
If the disease has spread to other organs, surgery and targeted therapies received quite a good response in addition to drugs that stimulate the immune system (immunotherapy) it is recommended to use. In recent years, it has been that very successful results have been obtained in these chemotherapy-resistant tumors with the combined use of immunotherapy and targeted agents.
.
.
.
.
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.